These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37753079)

  • 21. Severe eosinophilia and subsequent dermatologic immune-related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab.
    Matsumoto T; Kaneko A; Kusakabe Y; Nakayama E; Tanaka A; Yamamoto N; Aihara K; Yamaoka S; Mishima M
    Respirol Case Rep; 2022 Oct; 10(10):e01037. PubMed ID: 36176718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
    Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
    Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
    McQuade JL; Hammers H; Furberg H; Engert A; André T; Blumenschein G; Tannir N; Baron A; Larkin J; El-Khoueiry A; Carbone DP; Thomas JM; Hennicken D; Coffey M; Motzer RJ
    JAMA Oncol; 2023 Jan; 9(1):102-111. PubMed ID: 36480191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].
    Uhara H; Itakura E
    Gan To Kagaku Ryoho; 2019 Jun; 46(6):1017-1026. PubMed ID: 31273168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
    Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
    Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
    Krimmel L; Quante M; Bengsch B
    Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.
    Hara T; Furukawa J; Shiraishi Y; Okamura Y; Bando Y; Terakawa T; Harada K; Nakano Y; Fujisawa M
    Int J Urol; 2023 Sep; 30(9):746-752. PubMed ID: 37130778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
    Stenehjem D; Lubinga SJ; Wu A; Betts KA
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1054-1064. PubMed ID: 37610116
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
    Abdelhafeez AAM; Shohdy KS; Ibrahim W
    Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy.
    Montes G; Duval F; Eldani C; Amico S; Gérard E; Dutriaux C; Herran C; Poullenot F; Sole G; Carla L; Guerin C; Célerier P; Prey S
    J Immunother; 2021 Nov-Dec 01; 44(9):348-350. PubMed ID: 34166302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
    Cao Y; Afzal MZ; Shirai K
    BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
    Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
    Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
    Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2022 Apr; 19(4):216. PubMed ID: 35292750
    [No Abstract]   [Full Text] [Related]  

  • 40. Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report.
    Feng Y; Li C; Ji Y; Liu Y; Gan L; Yu Y; Liu T
    Front Oncol; 2022; 12():801924. PubMed ID: 35433482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.